With Suzhou RiboBio’s successful clearance of the Hong Kong Stock Exchange (HKEX) hearing, the Hong Kong market welcomes another highly scarce innovative biotech player. On December 21, HKEX disclosures confirmed that Suzhou RiboBio Technology Co., Ltd. ("RiboBio") has passed the listing hearing for the main board, with CICC and Citigroup serving as joint sponsors.
As a leading global developer in small interfering RNA (siRNA) therapeutics, RiboBio has built one of the world’s largest siRNA pipelines, with seven self-developed drug candidates in clinical trials. The small nucleic acid drug sector, where RiboBio operates, is regarded as the "third wave" following small molecules and antibody drugs. Compared to traditional therapies, siRNA offers broader target potential, shorter development cycles, and superior specificity—positioning it for rapid growth. According to Frost & Sullivan, the global siRNA market is projected to reach $18.6 billion by 2029, with a 29.5% CAGR from 2024 to 2029.
However, the industry faces high technical barriers, particularly in delivery systems—ensuring precise, efficient, and safe drug delivery to target organs (e.g., hepatic or extrahepatic tissues). Few companies like RiboBio have overcome these challenges and approached commercialization.
RiboBio’s success stems from its strategic pipeline, technological prowess, and execution. The company focuses exclusively on siRNA, addressing both rare and common diseases. Its clinical-stage assets include seven candidates targeting cardiovascular, metabolic, renal, and hepatic conditions, with four in Phase 2 trials. Notably, RBD1016 (targeting HDV) received EMA orphan drug designation in October 2025. Beyond these, RiboBio has over 20 preclinical projects.
Key highlights include: - **RBD4059**: The first and fastest-moving siRNA for thrombotic disorders (Phase 2a enrollment completed in February 2025). - **RBD5044**: The second global siRNA targeting APOC3 for hypertriglyceridemia (Phase 2 ongoing in Sweden). - **RBD7022**: The second siRNA against PCSK9 for hypercholesterolemia (Phase 1 completed in China; Phase 2 advanced by Qilu Pharma).
This diversified pipeline balances rare diseases (e.g., hereditary angioedema) with large-market indications (e.g., hypertension), ensuring near-term commercialization and long-term scalability.
Technologically, RiboBio has tackled the industry’s delivery bottleneck with its proprietary **RiboGalSTAR™** platform (GalNAc-based liver targeting), enhancing efficacy and safety. It also progresses in extrahepatic delivery (e.g., **RiboPepSTAR™** for kidneys/CNS and **RiboOncoSTAR™** for tumors), cementing its global leadership.
Financially, RiboBio’s revenue grew to RMB143 million in 2024 (H1 2025: RMB103 million), driven by partnerships with firms like Qilu Pharma and Boehringer Ingelheim. These collaborations validate its platform and fuel its transition from biotech to biopharma.
With overseas R&D centers, global clinical strategies, and a top-tier team, RiboBio is poised to reshape the global biopharma landscape. Its IPO offers investors a rare entry into China’s siRNA innovation wave.